Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LXRX NASDAQ:OSMT NASDAQ:SNDX NASDAQ:SYRS NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$1.42-3.4%$1.24$0.28▼$2.18$516.03M1.237.36 million shs1.69 million shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSNDXSyndax Pharmaceuticals$14.30-5.0%$15.49$8.58▼$22.50$1.23B0.682.23 million shs4.38 million shsSYRSSyros Pharmaceuticals$0.00+100.0%$0.00$0.00▼$0.10$11K1.31147,724 shs17,510 shsWVEWAVE Life Sciences$7.81-0.8%$8.07$5.28▼$16.74$1.24B-1.371.51 million shs1.76 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals-3.92%-10.37%+33.64%+19.51%-23.04%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals+0.07%-7.10%+0.07%+59.09%-24.33%SYRSSyros Pharmaceuticals-96.00%-96.00%-66.67%-98.00%-99.99%WVEWAVE Life Sciences-2.72%-3.91%+15.40%-5.64%-47.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$1.42-3.4%$1.24$0.28▼$2.18$516.03M1.237.36 million shs1.69 million shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSNDXSyndax Pharmaceuticals$14.30-5.0%$15.49$8.58▼$22.50$1.23B0.682.23 million shs4.38 million shsSYRSSyros Pharmaceuticals$0.00+100.0%$0.00$0.00▼$0.10$11K1.31147,724 shs17,510 shsWVEWAVE Life Sciences$7.81-0.8%$8.07$5.28▼$16.74$1.24B-1.371.51 million shs1.76 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals-3.92%-10.37%+33.64%+19.51%-23.04%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals+0.07%-7.10%+0.07%+59.09%-24.33%SYRSSyros Pharmaceuticals-96.00%-96.00%-66.67%-98.00%-99.99%WVEWAVE Life Sciences-2.72%-3.91%+15.40%-5.64%-47.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXRXLexicon Pharmaceuticals 2.29Hold$3.23127.11% UpsideOSMTOsmotica Pharmaceuticals 0.00N/AN/AN/ASNDXSyndax Pharmaceuticals 2.91Moderate Buy$38.00165.73% UpsideSYRSSyros Pharmaceuticals 2.00Hold$1.00249,900.00% UpsideWVEWAVE Life Sciences 2.79Moderate Buy$20.57163.40% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, OSMT, SYRS, SNDX, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.0010/15/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/8/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025WVEWAVE Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025WVEWAVE Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/5/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXRXLexicon Pharmaceuticals$31.08M16.60N/AN/A$0.40 per share3.55OSMTOsmotica Pharmaceuticals$177.88M0.00N/A1.00$1.50 per share0.00SNDXSyndax Pharmaceuticals$23.68M52.02N/AN/A$3.38 per share4.23SYRSSyros Pharmaceuticals$386K0.03N/AN/A$0.79 per share0.00WVEWAVE Life Sciences$108.30M11.48N/AN/A$1.37 per share5.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)OSMTOsmotica Pharmaceuticals-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/ASNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest LXRX, OSMT, SYRS, SNDX, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LXRXLexicon Pharmaceuticals-$0.07N/AN/AN/A$5.81 millionN/A11/11/2025Q3 2025WVEWAVE Life Sciences-$0.30N/AN/AN/A$9.85 millionN/A11/4/2025Q3 2025SNDXSyndax Pharmaceuticals-$0.73N/AN/AN/A$49.08 millionN/A8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXRXLexicon Pharmaceuticals0.434.164.16OSMTOsmotica PharmaceuticalsN/A0.430.42SNDXSyndax Pharmaceuticals2.064.714.55SYRSSyros PharmaceuticalsN/A2.252.25WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXRXLexicon Pharmaceuticals74.70%OSMTOsmotica Pharmaceuticals46.18%SNDXSyndax PharmaceuticalsN/ASYRSSyros Pharmaceuticals91.47%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipLXRXLexicon Pharmaceuticals13.90%OSMTOsmotica Pharmaceuticals5.22%SNDXSyndax Pharmaceuticals4.10%SYRSSyros Pharmaceuticals12.26%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableOSMTOsmotica Pharmaceuticals30262.59 million59.32 millionNot OptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableLXRX, OSMT, SYRS, SNDX, and WVE HeadlinesRecent News About These CompaniesClear Street Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationOctober 16 at 3:55 AM | msn.comWave Life Sciences initiated with a Buy at Clear StreetOctober 14 at 12:28 AM | msn.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from AnalystsOctober 14 at 2:15 AM | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 14 at 2:14 AM | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 5.3% - Here's What HappenedOctober 11, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 9.3% - Should You Buy?October 10, 2025 | marketbeat.comWave Life Sciences (WVE): A Valuation Deep Dive Following Pipeline Progress and Investor OptimismOctober 10, 2025 | finance.yahoo.comStrength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?October 10, 2025 | zacks.comWAVE Life Sciences' (WVE) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Wave Life Sciences (WVE)October 7, 2025 | theglobeandmail.comWave Life Sciences (WVE) Receives a Buy from Leerink PartnersOctober 7, 2025 | theglobeandmail.comWAVE Life Sciences Ltd. $WVE Stake Raised by Platinum Investment Management Ltd.October 2, 2025 | marketbeat.comInvivyd appoints Wave Life Sciences CEO Paul Bolno to boardSeptember 25, 2025 | msn.comWave Life Sciences Highlights WVE-007 Obesity TreatmentSeptember 25, 2025 | msn.com50,300 Shares in WAVE Life Sciences Ltd. $WVE Acquired by Strs OhioSeptember 23, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 19, 2025 | marketbeat.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025September 18, 2025 | zacks.comWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor ConferencesSeptember 18, 2025 | globenewswire.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comWave Life Sciences Announces Positive Results for WVE-006 StudySeptember 8, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, OSMT, SYRS, SNDX, and WVE Company DescriptionsLexicon Pharmaceuticals NASDAQ:LXRX$1.42 -0.05 (-3.40%) Closing price 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.46%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Osmotica Pharmaceuticals NASDAQ:OSMTOsmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.Syndax Pharmaceuticals NASDAQ:SNDX$14.30 -0.75 (-4.98%) Closing price 04:00 PM EasternExtended Trading$14.54 +0.24 (+1.68%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Syros Pharmaceuticals NASDAQ:SYRS$0.0004 +0.00 (+100.00%) As of 03:24 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.WAVE Life Sciences NASDAQ:WVE$7.81 -0.06 (-0.76%) Closing price 04:00 PM EasternExtended Trading$7.74 -0.06 (-0.83%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Energy Crunch Ahead: 3 Natural Gas Stocks Set to Gain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
